Sudden vision loss in one eye demands immediate emergency care
Britain's medicines regulator has issued a safety alert for the 1.6 million UK users of semaglutide-based drugs — Ozempic, Wegovy, and Rybelsus — warning of an extremely rare but serious eye condition called NAION, which can cause sudden, painless vision loss in one eye. The MHRA's alert, arriving just days after a separate warning about acute pancreatitis risk from the same class of drugs, reflects the broader challenge of monitoring widely adopted medicines as their use scales across populations. Though the risk remains vanishingly small, the consequences are serious enough that regulators are asking patients to treat any sudden vision change as a medical emergency — a reminder that even celebrated treatments carry shadows worth watching.
- Sudden, painless vision loss in one eye is the warning sign: a rare but serious condition called NAION, in which blood flow to the optic nerve abruptly drops, can affect semaglutide users without any prior indication.
- The alert lands just days after a separate MHRA warning about acute pancreatitis risk from GLP-1 drugs, creating a pattern of back-to-back safety communications that may unsettle the 1.6 million UK patients currently taking these medications.
- Regulators are careful to stress the risk is 'extremely small,' but the severity of potential outcomes — including lasting vision damage — means the alert cannot be treated as routine reassurance.
- Anyone experiencing sudden vision loss in one eye is urged to attend eye casualty or A&E immediately and report the incident through the MHRA's Yellow Card scheme, leaving no room for a wait-and-see approach.
- The MHRA frames both alerts as proactive safety monitoring rather than crisis response, signalling that as semaglutide use grows, regulators are actively scanning for and surfacing emerging risks in real time.
Britain's medicines regulator issued a safety alert on Thursday warning users of semaglutide-based drugs — Ozempic, Wegovy, and Rybelsus — to watch for sudden vision loss in one eye, a symptom of a rare but serious condition known as NAION. The condition occurs when blood flow to the front of the optic nerve suddenly drops, producing a painless blurring or clouding that typically affects just one eye. The MHRA describes the risk as extremely small, but serious enough to require immediate attendance at an eye casualty department or A&E.
Semaglutide belongs to a class of drugs called GLP-1 receptor agonists, which mimic a natural hormone regulating blood sugar and appetite. Prescribed under different brand names for type 2 diabetes and weight management, the medication has become one of the UK's most widely used treatments, with roughly 1.6 million people taking it over the past year.
MHRA Chief Safety Officer Dr. Alison Cave framed the alert as part of continuous safety monitoring, urging both patients and clinicians to recognise the warning signs and report any incidents through the Yellow Card scheme. The alert follows a separate warning issued just last week about the risk of acute pancreatitis — severe abdominal and back pain — from the same class of drugs, though Cave has consistently noted that for most patients, GLP-1 medicines remain safe and effective.
The two alerts in quick succession point to a broader dynamic: as these medications reach millions of users, regulators are identifying and communicating emerging risks with increasing frequency. The message to patients is straightforward — any sudden change in vision or unexplained severe pain warrants immediate emergency care, without hesitation.
Britain's medicines regulator has issued a fresh safety alert for the millions of people taking semaglutide-based drugs, warning them to watch for a rare but serious eye condition that can strike without warning. The Medicines and Healthcare products Regulatory Agency (MHRA) flagged the risk on Thursday, urging users of Ozempic, Wegovy, and Rybelsus to seek emergency care immediately if they experience sudden vision loss in one eye.
The condition in question is Non-Arteritic Anterior Ischemic Optic Neuropathy, or NAION—a medical term for what happens when blood flow to the front of the optic nerve suddenly drops. Patients who have experienced it describe the sensation as a blurring or clouding that appears without pain, typically affecting just one eye. The MHRA emphasizes the risk is "extremely small," but the consequences are serious enough to warrant immediate attention at an eye casualty department or accident and emergency.
Semaglutide is a glucagon-like peptide-1 receptor agonist, a class of drug that works by mimicking a natural hormone that regulates blood sugar and appetite. It comes under three brand names depending on its use: Ozempic and Rybelsus are prescribed for type 2 diabetes, while Wegovy is marketed for weight loss and reducing cardiovascular risk in people who are overweight or obese. The medication has become remarkably widespread—roughly 1.6 million people in the UK used it over a twelve-month period.
Dr. Alison Cave, the MHRA's Chief Safety Officer, framed the alert as part of the regulator's continuous monitoring of licensed medicines. "Patient safety is the MHRA's top priority," she said, acknowledging that while the potential risk is extremely small, both patients and healthcare professionals need to recognize the warning signs. Anyone taking semaglutide who notices sudden vision loss in one eye should attend eye casualty or A&E and report the incident through the MHRA's Yellow Card reporting scheme.
This latest warning arrives just days after the MHRA issued a separate alert about GLP-1 drugs, including semaglutide. Last week, regulators warned users to watch for severe abdominal and back pain that does not resolve, as this could signal acute pancreatitis—inflammation of the pancreas. Most people who develop pancreatitis recover within about a week without lasting complications, though some can experience more severe outcomes. Cave noted at that time that for the vast majority of patients prescribed GLP-1 drugs, they remain safe and effective medicines that deliver significant health benefits.
The back-to-back alerts underscore a pattern: as these medications have become more widely used, regulators are identifying and communicating emerging risks with greater frequency. The MHRA's approach suggests a careful balance—acknowledging that serious side effects are genuinely rare while ensuring that the millions of people taking these drugs know what symptoms demand immediate medical attention. For users, the message is clear: stay alert to changes in your vision or unexplained severe pain, and don't hesitate to seek emergency care if either appears.
Citas Notables
Patient safety is the MHRA's top priority and we continually monitor the safety and efficacy of all licensed medicines.— Dr. Alison Cave, MHRA Chief Safety Officer
For the vast majority of patients who are prescribed GLP-1s, they are safe and effective medicines which deliver significant health benefits.— Dr. Alison Cave, MHRA Chief Safety Officer
La Conversación del Hearth Otra perspectiva de la historia
Why is the MHRA issuing warnings about side effects that are described as extremely rare? Doesn't that risk causing unnecessary alarm?
There's a difference between rare and impossible. When a condition is serious enough to cause sudden blindness, even an extremely small risk becomes worth communicating clearly. The regulator's job is to make sure people can recognize danger if it happens to them.
But 1.6 million people are using these drugs. If the risk is truly tiny, wouldn't we expect to see many more cases by now?
That's exactly the point—we're not seeing many cases, which is why it's still classified as extremely rare. But the MHRA monitors adverse event reports constantly. When they start seeing a pattern, even a small one, they have an obligation to flag it so doctors and patients can watch for it.
What's the practical impact on someone taking Wegovy for weight loss? Does this change whether they should continue?
The MHRA isn't telling people to stop taking the medication. They're saying: know what sudden vision loss looks like, and if it happens, get to an emergency department immediately. For most people, the benefits of the drug outweigh the risks. But you need to be informed.
Two warnings in a week seems like a lot. Is semaglutide becoming less safe, or are regulators just catching up?
It's probably both. As millions more people use a drug, you see more rare side effects emerge. And regulators are getting better at detecting patterns in safety data. These aren't new problems—they're newly visible ones.
If someone's already on the drug and hasn't had problems, should they be worried?
Not worried, but aware. The condition is extremely rare. But if you suddenly can't see clearly out of one eye, you'll know exactly what to do and where to go.